search
Back to results

Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (CRUSADE-1)

Primary Purpose

HCV

Status
Withdrawn
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
sofosbuvir/velpatasvir tablet
sofosbuvir/velpatasvir crushed
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for HCV focused on measuring Epclusa, Pharmacokinetics, Crushing

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with SOF/VEL treatment for the treatment of chronic HCV genotype 1 through 6.
  2. Patient is at least 18 at the day of screening.
  3. Patient is able and willing to sign the Informed Consent Form.
  4. Patient is able and willing to follow protocol requirements.

Exclusion Criteria:

  1. Pregnant female (as confirmed by an hCG urine test performed at screening) or breast-feeding female.
  2. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
  3. Inability to understand the nature and extent of the study and the procedures required.
  4. Clinically relevant low hemoglobin concentration at screening judged by the patient's own hepatologist.

Sites / Locations

  • University of Bonn, Germany
  • Jeroen Bosch Hospital
  • Radboud university medical center Department of GI tract

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

sofosbuvir/velpatasvir tablet

sofosbuvir/velpatasvir crushed

Arm Description

Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.

Single-dose crushed sofosbuvir/velpatasvir in a fasted state.

Outcomes

Primary Outcome Measures

AUC
Cmax

Secondary Outcome Measures

Adverse events

Full Information

First Posted
September 25, 2017
Last Updated
December 4, 2020
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03389061
Brief Title
Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet
Acronym
CRUSADE-1
Official Title
Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Lack of patients who are eligible for inclusion: less patients on treatment and not using epclusa.
Study Start Date
April 1, 2018 (Actual)
Primary Completion Date
March 22, 2019 (Actual)
Study Completion Date
March 22, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Epclusa® is a pan-genotypic, once-daily tablet for the treatment of chronic hepatitis C virus (HCV) infection containing the NS5B- polymerase inhibitor sofosbuvir (SOF, nucleotide analogue) 400 mg and the NS5A inhibitor velpatasvir (VEL) 100 mg. For patients with swallowing difficulties, administration of whole tablets can be problematic. In addition, HCV patients that are hospitalized (at intensive care units) due to severe illness (co-infections/ liver failure) might not be able to swallow medication. Therefore it is useful to know whether it is possible to administer SOF/VEL through a different route, like a feeding tube. In daily practice, information about the safety and efficacy of crushed tablets is lacking which might result in interruption or discontinuation of expensive HCV therapy. However, it is not recommended to interrupt treatment because there is no evidence about the efficacy of the therapy after discontinuation (and restart). Currently, patients and healthcare professionals are crushing SOF/VEL tablets without information about efficacy and safety. Depending on the biopharmaceutical characteristics of a drug formulation, crushing tablets can lead to altered pharmacokinetics of drugs. It is important to know whether pharmacokinetic parameters are influenced by crushing of tablets; both a decrease and an increase in exposure may occur. A decrease of the plasma concentrations of SOF and/or VEL potentially reduces the therapeutic effect of the drugs. Higher doses or switching to other HCV-drugs might be needed. In contrast, in case a higher Cmax,ss and/or exposure occurs there might be an increased risk of toxicity. As a result, crushing the drug is a contra-indication based on the available data. Therefore this study will be conducted to investigate whether a crushed SOF/VEL tablet is bioequivalent to SOF/VEL as a whole tablet.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HCV
Keywords
Epclusa, Pharmacokinetics, Crushing

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Model Description
Bio-equivalence Study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
sofosbuvir/velpatasvir tablet
Arm Type
Active Comparator
Arm Description
Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.
Arm Title
sofosbuvir/velpatasvir crushed
Arm Type
Experimental
Arm Description
Single-dose crushed sofosbuvir/velpatasvir in a fasted state.
Intervention Type
Drug
Intervention Name(s)
sofosbuvir/velpatasvir tablet
Intervention Description
Single-dose SOF/VEL as a whole tablet in a fasted state.
Intervention Type
Drug
Intervention Name(s)
sofosbuvir/velpatasvir crushed
Intervention Description
Single-dose crushed SOF/VEL in a fasted state.
Primary Outcome Measure Information:
Title
AUC
Time Frame
Up to 24 hours after administration
Title
Cmax
Time Frame
one dosing interval after administration of SOF/VEL (up to 24 hours)
Secondary Outcome Measure Information:
Title
Adverse events
Time Frame
During the entire conduct of the study, maximum of two weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with SOF/VEL treatment for the treatment of chronic HCV genotype 1 through 6. Patient is at least 18 at the day of screening. Patient is able and willing to sign the Informed Consent Form. Patient is able and willing to follow protocol requirements. Exclusion Criteria: Pregnant female (as confirmed by an hCG urine test performed at screening) or breast-feeding female. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion. Inability to understand the nature and extent of the study and the procedures required. Clinically relevant low hemoglobin concentration at screening judged by the patient's own hepatologist.
Facility Information:
Facility Name
University of Bonn, Germany
City
Bonn
Country
Germany
Facility Name
Jeroen Bosch Hospital
City
's-Hertogenbosch
Country
Netherlands
Facility Name
Radboud university medical center Department of GI tract
City
Nijmegen
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32156618
Citation
van Seyen M, Samson AD, Cullen L, Eastick K, Knol H, Colbers A, Burger DM. Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder. Int J Antimicrob Agents. 2020 Jun;55(6):105934. doi: 10.1016/j.ijantimicag.2020.105934. Epub 2020 Mar 7. No abstract available.
Results Reference
result

Learn more about this trial

Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet

We'll reach out to this number within 24 hrs